Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.

Autor: Hailemichael Y; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Johnson DH; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Precision Cancer Therapies Program, Department of Hematology and Medical Oncology, Ochsner Health, New Orleans, LA, USA., Abdel-Wahab N; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Section of Rheumatology & Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Rheumatology and Rehabilitation, Assiut University Hospitals, Faculty of Medicine, Assiut University, Egypt., Foo WC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bentebibel SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daher M; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wani K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Saberian C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ogata D; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kim ST; Section of Rheumatology & Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nurieva R; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (GSBS), Houston, TX, USA., Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Abu-Sbeih H; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fa'ak F; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mathew A; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang Y; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Falohun A; Section of Rheumatology & Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Trinh V; Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zobniw C; Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Spillson C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burks JK; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Awiwi M; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Elsayes K; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Soto LS; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Melendez BD; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wargo J; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Curry J; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yee C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lizee G; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Singh S; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sharma P; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ekmekcioglu S; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: adiab@mdanderson.org.

Publikováno v: Cancer cell [Cancer Cell] 2022 May 09; Vol. 40 (5), pp. 509-523.e6. Date of Electronic Publication: 2022 May 09.

Societal Attitudes Towards Autism (SATA): Validation of the Greek Version in the General Population.

Autor: Zarokanellou, Vasiliki¹, Gryparis, Alexandros¹, Papatheodorou, Paraskevi¹, Tatsis, Giorgos¹, Tafiadis, Dionysios¹, Papadopoulos, Angelos², Voniati, Louiza³, Siafaka, Vassiliki¹ siafaka@uoi.gr

Publikováno v: Journal of Autism & Developmental Disorders. Apr2024, Vol. 54 Issue 4, p1582-1593. 12p.

Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management.

Autor: Moturi, Krishna¹ (AUTHOR) hrsharma@salud.unm.edu, Sharma, Harsh¹ (AUTHOR), Hashemi-Sadraei, Neda¹ (AUTHOR) kmoturi@salud.unm.edu

Publikováno v: International Journal of Molecular Sciences. Jan2024, Vol. 25 Issue 1, p414. 13p.

Do Autistic People's Support Needs and Non-Autistic People's Support for the Neurodiversity Movement Contribute to Heightened Autism Stigma in South Korea vs. the US?

Autor: Kim, So Yoon¹ soyoonkim@duksung.ac.kr, Gillespie-Lynch, Kristen²

Publikováno v: Journal of Autism & Developmental Disorders. Nov2023, Vol. 53 Issue 11, p4199-4213. 15p. 3 Charts.

Radiotherapy and gynaecological cancers during the pandemic: the role of hematologic toxicity.

Autor: Iorio, Giuseppe Carlo¹ giorio@cittadellasalute.to.it, Chiofalo, Valeria¹, Ricardi, Umberto¹

Publikováno v: European Journal of Gynaecological Oncology. Dec2023, Vol. 44 Issue 6, p1-3. 3p.